
|Videos|April 13, 2022
Urology Times 50 Innovations Series: Intralesional therapies for Peyronie's disease
Author(s)Urology Times staff
"Peyronie's disease has really seen a wide range of intralesional options through the years," says Denise Asafu-Adjei, MD, MPH.
Advertisement
Urology Times® is celebrating its 50th anniversary in 2022. To mark the occasion, we are highlighting 50 of the top innovations and developments that have transformed the field of urology over the past 50 years. In this installment, Denise Asafu-Adjei, MD, MPH, discusses the development of intralesional therapies for Peyronie’s disease and how they have improved the treatment of this condition. Asafu-Adjei is a urologist and medical director of male reproductive medicine at Loyola University, Chicago, Illinois.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Urology Times
1
The UroOnc Minute: Cribriform Histology in Prostate Cancer, With Tyler Seibert, MD, PhD
2
CMS' 2027 PFS proposed rule: Modifier -25 cuts, G2211 overhaul loom
3
Kari Tikkinen, MD, PhD, discusses POISE-3 findings on tranexamic acid in urologic surgery
4
Rezūm shows greater 1-year BPH symptom relief vs pharmacotherapy
5
















































